Monrol plans to open radiopharmaceutical facility in Germany

By staff writers

September 30, 2022 -- Istanbul-based Eczacibasi-Monrol Nuclear Products (Monrol) said it plans to open a facility in Germany to produce radiopharmaceuticals for imaging and radioligand therapy.

The manufacturing facility will be focused on producing gallium-68 and non-carrier-added lutetium-177, radiopharmaceuticals that are used to image and treat cancer, such as prostate cancer and neuroendocrine tumors, the company said.

The new facility is scheduled to be up and running by 2026 at an estimated cost of about 30 million euros.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking